# AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

> **NCT05578430** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 54 (estimated)

## Conditions studied

- Resectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cadonilimab
- **PROCEDURE:** TACE
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT05578430
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05578430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05578430, "AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05578430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*